A Phase 3 interventional study of Fulvestrant and Placebo in Breast Cancer, sponsored by AstraZeneca. Completed at 15 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-24.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 20th largest by enrollment of the 94 interventional ones that give a count, is one of 2 that started in 2011, is one of 21 in phase 3, and was the 39th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 249 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 45th largest by enrollment of the 125 interventional ones that give a count, is one of 5 that started in 2011, is one of 46 in phase 3, and was the 93rd registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment.
Fulvestrant, at a dose of 250mg every 28 days, is the first oestrogen receptor antagonist with no agonist effects shown to be at least as effective for both TTP (Time to Progression) and OR (Objective Response) as a third-generation aromatase inhibitor in the second-line treatment of advanced breast cancer (Howell et al 2002, Osborne CK et al 2002).In these studies overall survival was also similar between the fulvestrant and anastrozole treatment arms (Pippen J et al 2003). Fulvestrant has received approval in 70 countries worldwide at this dose regimen.
However, evidence from a number of studies suggests that higher dose may be able to enhance efficacy further:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only
Drug: Fulvestrant
Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only
Drug: Fulvestrant · Drug: Placebo
Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
Also known as: Faslodex
Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
Progression-free Survival
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of existing non-target lesions, or the appearance of new lesions, or death (by any cause in the absence of progression). The primary analysis for PFS was the log rank test stratified by last endocrine therapy received prior to fulvestrant (AO vs. AI). The treatment effect was estimated using the HR of 500 mg fulvestrant to 250 mg fulvestrant together with the corresponding 95% CI and p value.
Time frame: 36 months
Objective Response Rate
The ORR is defined as the proportion of all randomized patients with measurable disease at baseline who have a best objective tumour response of either CR or PR per RECIST v1.1.
Time frame: 36 months
Clinical Benefit Rate
A clinical benefit (CB) responder is defined as a patient having a best overall response of either CR, PR or SD for at least 24 weeks per RECIST v1.1. As tumour assessments can occur ± 2 weeks of the specified time point, the CBR is defined as the proportion of patients in the FAS who have CB ≥ 22 weeks (or 154 days).
Time frame: 36 months
Duration of Response
Duration of response (DoR) will be evaluated only for patients who have an objective response, and is defined as the time from the date of first documentation of objective response (i.e., the initial visit at which CR or PR was recorded) until the date of disease progression or death due to any cause (whichever is earlier). The time of the initial response will be defined as the latest of the dates contributing towards the first visit response of PR or CR. Any patient who has not progressed or died by the date of DCO, or who has been lost to follow up, will be right-censored at the date of their last disease assessment.
Time frame: 36 months
Duration of Clinical Benefit
Duration of clinical benefit (DoCB) will be evaluated only for patients who have CB, and is defined as the time from the date of randomisation until the date of disease progression or death from any cause, whichever is earlier. Any patient who has not progressed or died by the date of DCO or who has been lost to follow up will be right censored at the date of their last evaluable disease assessment.
Time frame: 36 months
The planned population size was 220 randomised patients. 249 patients were enrolled with 28 screen-failured patients and altogether 221 patients were randomised. The recuitment period of this study took 34 months, first subject in on 01 Mar 2011 and last subject in on 23 Dec 2013.
| Milestone | Fulvestrant 500 mg | Fulvestrant 250 mg |
|---|---|---|
| Started | 111 | 110 |
| Received study treatment | 109 | 110 |
| Completed | 75 | 72 |
| Not completed | 36 | 38 |
| Withdrew: Did not receive treatment | 2 | 0 |
| Withdrew: Ongoing treatment at data cut-off | 27 | 23 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 0 | 4 |
| Withdrew: Withdrawal by subject | 7 | 10 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of existing non-target lesions, or the appearance of new lesions, or death (by any cause in the absence of progression). The primary analysis for PFS was the log rank test stratified by last endocrine therapy received prior to fulvestrant (AO vs. AI). The treatment effect was estimated using the HR of 500 mg fulvestrant to 250 mg fulvestrant together with the corresponding 95% CI and p value.
| months | Fulvestrant 500 mg | Fulvestrant 250 mg |
|---|---|---|
| Progression-free Survival | 8.0 (2.8 to 16.6) | 4.0 (2.7 to 11.1) |
The ORR is defined as the proportion of all randomized patients with measurable disease at baseline who have a best objective tumour response of either CR or PR per RECIST v1.1.
| patients | Fulvestrant 500 mg | Fulvestrant 250 mg |
|---|---|---|
| Objective Response Rate | 16 (5.36 to 11.04) | 11 (2.92 to 5.72) |
A clinical benefit (CB) responder is defined as a patient having a best overall response of either CR, PR or SD for at least 24 weeks per RECIST v1.1. As tumour assessments can occur ± 2 weeks of the specified time point, the CBR is defined as the proportion of patients in the FAS who have CB ≥ 22 weeks (or 154 days).
| patients | Fulvestrant 500 mg | Fulvestrant 250 mg |
|---|---|---|
| Clinical Benefit Rate | 53 | 36 |
Duration of response (DoR) will be evaluated only for patients who have an objective response, and is defined as the time from the date of first documentation of objective response (i.e., the initial visit at which CR or PR was recorded) until the date of disease progression or death due to any cause (whichever is earlier). The time of the initial response will be defined as the latest of the dates contributing towards the first visit response of PR or CR. Any patient who has not progressed or died by the date of DCO, or who has been lost to follow up, will be right-censored at the date of their last disease assessment.
| months | Fulvestrant 500 mg | Fulvestrant 250 mg |
|---|---|---|
| Duration of Response | 16.6 (5.6 to NA) | 22.2 (10.8 to NA) |
Duration of clinical benefit (DoCB) will be evaluated only for patients who have CB, and is defined as the time from the date of randomisation until the date of disease progression or death from any cause, whichever is earlier. Any patient who has not progressed or died by the date of DCO or who has been lost to follow up will be right censored at the date of their last evaluable disease assessment.
| months | Fulvestrant 500 mg | Fulvestrant 250 mg |
|---|---|---|
| Duration of Clinical Benefit | 14.3 (11.0 to 25.0) | 13.8 (11.0 to NA) |
Collected over Adverse Events will be collected from time of signature of informed consent throughout the treatment period and up to 8 weeks after the last injection of study medication.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant 500 mg | — | 4/109 (3.7%) | 68/109 (62.4%) |
| Fulvestrant 250 mg | — | 9/110 (8.2%) | 65/110 (59.1%) |
| Event | Fulvestrant 500 mg | Fulvestrant 250 mg |
|---|---|---|
| PyrexiaGeneral disorders | 1/109 | 2/110 |
| Arthritis bacterialInfections and infestations | 0/109 | 2/110 |
| Hepatic function abnormalHepatobiliary disorders | 1/109 | 0/110 |
| Haemoglobin decreasedInvestigations | 1/109 | 1/110 |
| Bone painMusculoskeletal and connective tissue disorders | 1/109 | 0/110 |
| Cerebral infarctionNervous system disorders | 1/109 | 0/110 |
| AnaemiaBlood and lymphatic system disorders | 0/109 | 1/110 |
| Cardiac failureCardiac disorders | 0/109 | 1/110 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/109 | 1/110 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/109 | 1/110 |
| Event | Fulvestrant 500 mg | Fulvestrant 250 mg |
|---|---|---|
| INJECTION SITE REACTIONGeneral disorders | 12/109 | 13/110 |
| PYREXIAGeneral disorders | 11/109 | 6/110 |
| INJECTION SITE PAINGeneral disorders | 8/109 | 10/110 |
| FATIGUEGeneral disorders | 9/109 | 7/110 |
| BACK PAINMusculoskeletal and connective tissue disorders | 8/109 | 4/110 |
| HEADACHENervous system disorders | 7/109 | 4/110 |
| NAUSEAGastrointestinal disorders | 6/109 | 7/110 |
| COUGHRespiratory, thoracic and mediastinal disorders | 2/109 | 6/110 |
| WHITE BLOOD CELL COUNT DECREASEDInvestigations | 5/109 | 2/110 |
| VOMITINGGastrointestinal disorders | 4/109 | 2/110 |
The planned population size was 220 randomised patients and altogether 221 patients were randomised. Key demographic and baseline characteristics were balanced between the treatment groups.
| Age, Continuous(years) | Fulvestrant 500 mg | Fulvestrant 250 mg | Total |
|---|---|---|---|
| Mean | 53.6 ± 10.12 | 53.1 ± 10.22 | 53.3 ± 10.15 |
| Age, Customized(participants) | Fulvestrant 500 mg | Fulvestrant 250 mg | Total |
|---|---|---|---|
| <50 Years | 37 | 40 | 77 |
| ≥50 to <65 Years | 61 | 56 | 117 |
| ≥65 Years | 13 | 14 | 27 |
| Sex: Female, Male(Participants) | Fulvestrant 500 mg | Fulvestrant 250 mg | Total |
|---|---|---|---|
| Female | 111 | 110 | 221 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Fulvestrant 500 mg | Fulvestrant 250 mg | Total |
|---|---|---|---|
| Asian | 111 | 110 | 221 |
| Weight(kg) | Fulvestrant 500 mg | Fulvestrant 250 mg | Total |
|---|---|---|---|
| Mean | 61.0 (35.0 to 85.0) | 60.5 (42.0 to 88.0) | 60.7 (35.0 to 88.0) |
| WHO Performance Status(participants) | Fulvestrant 500 mg | Fulvestrant 250 mg | Total |
|---|---|---|---|
| (0) Normal activity | 80 | 77 | 157 |
| (1) Restricted activity | 28 | 30 | 58 |
| (2) In bed ≤50% of the time | 3 | 3 | 6 |
| Extent of disease at baseline(participants) | Fulvestrant 500 mg | Fulvestrant 250 mg | Total |
|---|---|---|---|
| Locally advanced breast cancer only | 1 | 1 | 2 |
| Metastatic disease | 110 | 109 | 219 |
The record gives a start of Mar 2011, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant